This CME program will highlight updates in the multiple sclerosis treatment landscape, including anti-CD20 therapeutics. The expert faculty, Dr. Grace Gombolay, will first utilize a case-based format to review current guidelines as well as the typical clinical course in multiple sclerosis. Following, recent clinical trial data of both B-cell depleting and anti-CD20 therapeutics will be analyzed, along with the implications for clinical practice. The expert faculty will conclude with an overview of future emerging therapies in multiple sclerosis, as well as practical tips for administering effective patient education to improve outcomes and quality of life.
MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis
Review recent efficacy and safety data for anti-CD20 therapeutics to treat patients with multiple sclerosis
Recognize the current unmet needs of patients with MS and the role of anti-CD20 therapeutics to improve outcomes for these patients
Data Update on Anti-CD20 Therapeutics for the Management of Patients with Multiple Sclerosis
Individualized Treatment Plans: The Role of Anti-CD20 Therapeutics to Improve Outcomes and Address the Unmet Needs of Patients with MS
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Grace Gombolay, MD | Nothing to disclose |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Learners should only claim credit commensurate with the extent of their participation.
This activity has been supported by an independent educational grant from TG Therapeutics.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and TG Therapeutics do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
